As investigations mount and controversy swirls, Biogen fights back against ICER — and then faces another unanimous slapdown
There’s been no shortage of words written about Biogen’s new Alzheimer’s drug, Aduhelm, since its controversial approval last month. And on Thursday, the biotech attempted to push back against the narrative, blasting a report from the Institute for Clinical and Economic Review characterizing the evidence behind the drug as “insufficient.”
During a panel convened by the California Technology Assessment Forum, Biogen chief medical officer Maha Radhakrishnan vilified the ICER report as “inappropriate” and “fundamentally flawed.” Radhakrishnan particularly objected to ICER’s “blending” of the two Phase III trials in its analysis, leading to its flaws.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.